trimetrexate has been researched along with Osteosarcoma in 3 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "By this procedure a subline of Burkitt's lymphoma cells (RAJI) was made 290-fold resistant (RAJI/MTX-R), T-cell leukemia cells (CCRF-CEM) were obtained 210-fold resistant (CEM/MTX-R), and 3 MTX-resistant human osteosarcoma lines were selected: TE-85/MTX-R (19-fold resistant; relative to wild-type); MG-63/MTX-R (8-fold resistant); and SAOS-2/MTX-R (200-fold resistant)." | 5.27 | Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. ( Diddens, H; Jackson, RC; Niethammer, D, 1983) |
| " The antifolate drug most commonly used for treating human tumors is methotrexate (MTX), which is utilized widely in first-line treatment protocols of high-grade osteosarcoma (HGOS)." | 4.95 | Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. ( Fanelli, M; Hattinger, CM; Picci, P; Serra, M; Tavanti, E; Vella, S, 2017) |
| "By this procedure a subline of Burkitt's lymphoma cells (RAJI) was made 290-fold resistant (RAJI/MTX-R), T-cell leukemia cells (CCRF-CEM) were obtained 210-fold resistant (CEM/MTX-R), and 3 MTX-resistant human osteosarcoma lines were selected: TE-85/MTX-R (19-fold resistant; relative to wild-type); MG-63/MTX-R (8-fold resistant); and SAOS-2/MTX-R (200-fold resistant)." | 1.27 | Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. ( Diddens, H; Jackson, RC; Niethammer, D, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hattinger, CM | 1 |
| Tavanti, E | 1 |
| Fanelli, M | 1 |
| Vella, S | 1 |
| Picci, P | 1 |
| Serra, M | 1 |
| Diddens, H | 2 |
| Niethammer, D | 2 |
| Jackson, RC | 2 |
1 review available for trimetrexate and Osteosarcoma
| Article | Year |
|---|---|
Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Folic Acid Antagonists; Humans; Methotrexate; Neopl | 2017 |
2 other studies available for trimetrexate and Osteosarcoma
| Article | Year |
|---|---|
Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Topics: Antineoplastic Agents; Biological Transport; Burkitt Lymphoma; Cell Line; Drug Resistance; Folic Aci | 1983 |
Resistance of human tumor cell lines to antifolates.
Topics: B-Lymphocytes; Biological Transport; Cell Line; Drug Resistance; Folic Acid; Folic Acid Antagonists; | 1984 |